Breaux/Thomas Compromise With Clinton Could Begin At $90 Bil. For Drugs
Executive Summary
A $90 bil. allocation over 10 years could be enough for a workable political compromise for the start-up of a Medicare drug benefit, Progressive Policy Institute Senior Economist Jeff Lemieux suggested at a Capitol Hill forum Sept. 13.
You may also be interested in...
White House Using PBM Buzz To Diffuse Price Control Criticisms
The White House is substituting pharmacy benefit managers for price controls as the rhetorical centerpiece of the Administration's second attempt to provide government prescription drug coverage to seniors.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials